🔗 Share this article

While the US undertakes unprecedented changes to its vaccination recommendations, a particular individual appears unexpectedly: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning COVID-19 vaccinations during the global health crisis and has focused upon possible deaths after Covid immunization in her brief time at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Program

Public health authorities planned to unveil major changes to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, according to reports – a major change that would put the US out of alignment with much of the world with little proof for improved outcomes. This reveal has been pushed back until the coming year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to speak at the meeting. She was just designated interim head of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood shot schedules in the US to become more similar to Denmark, a country with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – usually the responsibility of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Background

Høeg has no obvious background in pharmaceutical research, approval processes or administrative roles, which has been typical for former leaders of the CBER. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She is not an expert in drug approvals.”

Previous heads of CBER would “be deeply familiar with legal statutes and the science of drug development”, said Janet Woodcock. “Clearly, she lacks the type of experience that former directors who ran CBER have had.”

The drug center has an enormous workload at the FDA, the former commissioner emphasized.

“Everybody just pays attention on the new drug program, but the generic drug division authorizes numerous generic medications. There is also a biologic copycat branch, OTC medication office and more, and all of those need to be supervised,” Woodcock said. “The area you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major management element to the role, which oversees more than 5,000 employees. “It’s a enormous management job, if you do it right,” she concluded.

Agency Reaction and Contentious Policies

Regarding concerns about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among agency officials on immunizations, a press secretary stated that the “inquiries rely on inaccurate presumptions”.

“This background aligns with the duties of her position,” the representative stated, pointing to the months Dr. Høeg spent advising the agency head on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious one-day drug-approval program that apparently worried her predecessors. “How are these medications being chosen for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards less stringent regulations of all drugs, except for vaccines.”

Public Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if concerning, past, Howard observe. She published a research paper using unverified volunteer-provided data to assess the frequency of myocarditis following COVID-19 vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming federal leadership encompassed changing guidelines for novel immunizations and halting “optional” vaccines, she stated following the vote on a audio program. At the FDA, Høeg has allegedly floated the idea of excluding young men from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her conclusions and reverse-engineers to retrofit the evidence in a very disingenuous, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other dissenters, {like|